Michael Katovich, Ph.D.
Professor Emeritus
Teaching Profile
Courses Taught
2008-2012,2015-2016
PHA6910 Supervised Research
2006,2008-2016
PHA7980 Research for Doctoral Dissertation
2007-2012,2014-2016
PHA7979 Advanced Research
2006-2007,2009-2016,2015-2016
PHA6936 Advanced Topics in Pharmaceutical Sciences
2016
PHA4911 Undergraduate Research in Pharmacodynamics
2008-2012,2015-2016
PHA6512L Experiential Research Training in Pharmacodynamics
2016
GMS7003 Respon Conduct Biomed
2011-2012,2014-2015
PHA6521C Research Techniques in Pharmacodynamics
2012-2015
PHA5561C Physiol Bas Disease 2
2013-2015
PHA6509 Systems Physiology and Pathophysiology II
2014
PHA6508 Systems Physiology and Pathophysiology I
2010-2014
PHA5560C Physiol Bas Disease 1
2010-2011,2013-2014
PHA7939 Journal Colloquy in Pharmacodynamics
2007,2009-2013,2013-2014
PHA6938 Research Seminar
2010,2012-2013
PHA5902 Research Pharmacodyna
2010-2012
PHA6971 Masters Research
2010
PHA5933 Select Top Pharmacy
2010
PHA4902 Prob Pharmacodynamics
2010
PHA6540 Neurochem Founda
Research Profile
The Katovich Lab studies the various components of the endocrine renin-angiotensin system (RAS) and their effects on hypertension and associated cardiovascular organ damage. Over the past several years more components of the RAS have been elucidated and we have utilized gene therapy approaches to enhance and/or modify certain aspects of the RAS in order to reduce cardiovascular risks in hypertension and diabetes. We utilize in vivo animal models as well as cell culture protocols to evaluate the physiological, pharmacological and morphological effects of manipulations of the RAS. Currently we are looking at the effects of overexpressing components of the RAS such as the AT2R, ACE2 and Ang-(1-7) in models of hypertension, stroke, and coronary artery ligation to determine the “beneficial” effects of these RAS components on various end organs. Utilization of gene therapy approaches and classical physiological methods (such as vascular smooth muscle reactivity, in vitro heart perfusion, metabolic studies, etc) aid in not only the understanding of the mechanism of actions of existing therapeutic agents but also leads to new innovative therapeutic effects in treating cardiovascular and metabolic diseases.
Publications
2019
Complementary Embryonic and Adult Cell Populations Enhance Myocardial Repair in Rat Myocardial Injury Model.
Stem cells international.
2019
[DOI] 10.1155/2019/3945850.
[PMID] 31781239.
2018
Beneficial Effects of Angiotensin-(1-7) on CD34+ Cells From Patients With Heart Failure.
Journal of cardiovascular pharmacology.
71(3):155-159
[DOI] 10.1097/FJC.0000000000000556.
[PMID] 29140957.
2018
Coupling corticotropin-releasing-hormone and angiotensin converting enzyme 2 dampens stress responsiveness in male mice.
Neuropharmacology.
133:85-93
[DOI] 10.1016/j.neuropharm.2018.01.025.
[PMID] 29360543.
2018
Involvement of Neuroinflammation in the Pathogenesis of Monocrotaline-Induced Pulmonary Hypertension.
Hypertension (Dallas, Tex. : 1979).
71(6):1156-1163
[DOI] 10.1161/HYPERTENSIONAHA.118.10934.
[PMID] 29712738.
2018
The Selective Angiotensin II Type 2 Receptor Agonist, Compound 21, Attenuates the Progression of Lung Fibrosis and Pulmonary Hypertension in an Experimental Model of Bleomycin-Induced Lung Injury.
Frontiers in physiology.
9
[DOI] 10.3389/fphys.2018.00180.
[PMID] 29636695.
2016
Angiotensin-(1-7) Decreases Cell Growth and Angiogenesis of Human Nasopharyngeal Carcinoma Xenografts.
Molecular cancer therapeutics.
15(1):37-47
[DOI] 10.1158/1535-7163.MCT-14-0981.
[PMID] 26671566.
2016
Angiotensin-converting enzyme 2 inhibits high-mobility group box 1 and attenuates cardiac dysfunction post-myocardial ischemia.
Journal of molecular medicine (Berlin, Germany).
94(1):37-49
[PMID] 26498282.
2016
Increasing brain angiotensin converting enzyme 2 activity decreases anxiety-like behavior in male mice by activating central Mas receptors.
Neuropharmacology.
105:114-123
[DOI] 10.1016/j.neuropharm.2015.12.026.
[PMID] 26767952.
2016
Therapeutic potential of adipose stem cell-derived conditioned medium against pulmonary hypertension and lung fibrosis.
British journal of pharmacology.
173(19):2859-79
[DOI] 10.1111/bph.13562.
[PMID] 27448286.
2015
ACE2 and Microbiota: Emerging Targets for Cardiopulmonary Disease Therapy.
Journal of cardiovascular pharmacology.
66(6):540-50
[DOI] 10.1097/FJC.0000000000000307.
[PMID] 26322922.
2015
Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis.
British journal of pharmacology.
172(9):2219-31
[DOI] 10.1111/bph.13044.
[PMID] 25522140.
2014
Is angiotensin II type 2 receptor a new therapeutic target for cardiovascular disease?
Experimental physiology.
99(7):933-4
[DOI] 10.1113/expphysiol.2014.080705.
[PMID] 24987019.
2014
Neuroinflammation in pulmonary hypertension: concept, facts, and relevance.
Current hypertension reports.
16(9)
[DOI] 10.1007/s11906-014-0469-1.
[PMID] 25090964.
2014
Oral delivery of Angiotensin-converting enzyme 2 and Angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension.
Hypertension (Dallas, Tex. : 1979).
64(6):1248-59
[DOI] 10.1161/HYPERTENSIONAHA.114.03871.
[PMID] 25225206.
2014
The angiotensin type 2 receptor agonist Compound 21 elicits cerebroprotection in endothelin-1 induced ischemic stroke.
Neuropharmacology.
81:134-41
[DOI] 10.1016/j.neuropharm.2014.01.044.
[PMID] 24508710.
2013
Ace2 Activation Ameliorates Endothelial Function in the Right Ventricles of Pulmonary Hypertensive Rats
The FASEB's Journal.
27
2013
Angiotensin Converting Enzyme-2 Activation Attenuates Right Ventricular Hypertrophy and Dysfunction After Pulmonary Artery Banding in Rats
Circulation.
128(22, S)
2013
Angiotensin-converting enzyme 2 activation improves endothelial function.
Hypertension (Dallas, Tex. : 1979).
61(6):1233-8
[DOI] 10.1161/HYPERTENSIONAHA.111.00627.
[PMID] 23608648.
2013
Chronic knockdown of the nucleus of the solitary tract AT1 receptors increases blood inflammatory-endothelial progenitor cell ratio and exacerbates hypertension in the spontaneously hypertensive rat.
Hypertension (Dallas, Tex. : 1979).
61(6):1328-33
[DOI] 10.1161/HYPERTENSIONAHA.111.00156.
[PMID] 23547238.
2013
Comparison of the transduction efficiency of tyrosine-mutant adeno-associated virus serotype vectors in kidney.
Clinical and experimental pharmacology & physiology.
40(1):53-5
[DOI] 10.1111/1440-1681.12037.
[PMID] 23216315.
2013
Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology.
Hypertension (Dallas, Tex. : 1979).
62(4):746-52
[DOI] 10.1161/HYPERTENSIONAHA.113.01337.
[PMID] 23959549.
2013
Diminazene aceturate improves autonomic modulation in pulmonary hypertension.
European journal of pharmacology.
713(1-3):89-93
[DOI] 10.1016/j.ejphar.2013.04.017.
[PMID] 23665493.
2013
Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models.
American journal of respiratory and critical care medicine.
187(6):648-57
[DOI] 10.1164/rccm.201205-0880OC.
[PMID] 23370913.
2013
Genetically Engineered Mesenchymal Stem Cells That Overexpress Ace2 Or Angiotensin-(1-7) Show Enhanced Nitric-Oxide Production
The FASEB's Journal.
27
2013
Lenti-Angiotensin-(1-7) Transduction of Islet Plus Cardiac Progenitor Cells Improves the Reparative Capacity in Doxorubicin Induced Cardiomyopathy
The FASEB's Journal.
27
2013
Small Molecule Ace2 Activator, Diminazene Aceturate (Dize) Attenuates Mi-Induced Cardiac Pathophysiology
The FASEB's Journal.
27
2012
Effect of Dize, An Ace2 Activator On Cardiopulmonary Fibrosis and Apoptosis
Critical Care Medicine.
40
2012
Moderate cardiac-selective overexpression of angiotensin II type 2 receptor protects cardiac functions from ischaemic injury.
Experimental physiology.
97(1):89-101
[DOI] 10.1113/expphysiol.2011.060673.
[PMID] 21967903.
2012
Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction.
Regulatory peptides.
177(1-3):107-15
[DOI] 10.1016/j.regpep.2012.05.093.
[PMID] 22595130.
2011
Ace2 Activation Improves Endothelial Function By Attenuation of Oxidative Stress
Hypertension.
58
2011
ACE2, a promising therapeutic target for pulmonary hypertension.
Current opinion in pharmacology.
11(2):150-5
[DOI] 10.1016/j.coph.2010.12.002.
[PMID] 21215698.
2011
An Ace2 Activator (Dize) Improves Endothelial Progenitor Cell Function and Attenuates Pulmonary Hypertension
Hypertension.
58
2011
Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases.
Experimental physiology.
96(3):287-94
[DOI] 10.1113/expphysiol.2010.055277.
[PMID] 21148624.
2011
Cardiac Progenitor Cells (Islet-1(+)) Restore Myocardial Infarction Induced Cardiac Dysfunction and Remodeling
Hypertension.
58
2011
Cerebroprotection by angiotensin-(1-7) in endothelin-1-induced ischaemic stroke.
Experimental physiology.
96(10):1084-96
[DOI] 10.1113/expphysiol.2011.058578.
[PMID] 21685445.
2011
Lentivirus-mediated overexpression of angiotensin-(1-7) attenuated ischaemia-induced cardiac pathophysiology.
Experimental physiology.
96(9):863-74
[DOI] 10.1113/expphysiol.2011.056994.
[PMID] 21685447.
2011
Oral Administration of An Angiotensin-Converting Enzyme 2 Activator Improves Diabetes-Induced Cardiovascular Dysfunction
Hypertension.
58
2010
Ace2 Activation Improves Endothelial Function
Arteriosclerosis Thrombosis and Vascular Biology.
30
2010
Ace2 Activation Improves Endothelial Function of Diabetic Rats
Hypertension.
56
2010
Ace2 Activation Improves Endothelial Function of Diabetic Rats
Hypertension.
56
2010
ACE2 activation promotes antithrombotic activity.
Molecular medicine (Cambridge, Mass.).
16(5-6):210-5
[DOI] 10.2119/molmed.2009.00160.
[PMID] 20111697.
2010
Activation of the Protective Arm of Renin Angiotensin System (Ras) Corrects the Reparative Dysfunction of Diabetic Cd34+Cells
Blood.
116:1087-1088
2010
Brain microglial cytokines in neurogenic hypertension.
Hypertension (Dallas, Tex. : 1979).
56(2):297-303
[DOI] 10.1161/HYPERTENSIONAHA.110.150409.
[PMID] 20547972.
2010
Diabetes-Induced Cardiovascular Dysfunction Is Improved By Angiotensin-Converting Enzyme 2 Activation: Modulation of Ace/Ang Ii/At1R and Ace2/Ang-(1-7)/Mas Receptor Axes
Hypertension.
56
2010
Involvement of the Brain (Pro) Renin Receptor in Cardiovascular Homeostasis
Hypertension.
56
2010
Involvement of the brain (pro)renin receptor in cardiovascular homeostasis.
Circulation research.
107(7):934-8
[DOI] 10.1161/CIRCRESAHA.110.226977.
[PMID] 20689062.
2010
NT79: A novel neurotensin analog with selective behavioral effects.
Brain research.
1308:35-46
[DOI] 10.1016/j.brainres.2009.10.050.
[PMID] 19874804.
2010
Selective tropism of the recombinant adeno-associated virus 9 serotype for rat cardiac tissue.
The journal of gene medicine.
12(1):22-34
[DOI] 10.1002/jgm.1404.
[PMID] 19830780.
2010
The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension.
American journal of respiratory and critical care medicine.
182(8):1065-72
[DOI] 10.1164/rccm.200912-1840OC.
[PMID] 20581171.
2010
Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases.
Hypertension (Dallas, Tex. : 1979).
55(2):207-13
[DOI] 10.1161/HYPERTENSIONAHA.109.140145.
[PMID] 20038757.
2010
Xnt, a Synthetic Ace2 Activator, Improves Endothelial Function
Journal of Hypertension.
28
2009
17beta-Estradiol modulates local cardiac renin-angiotensin system to prevent cardiac remodeling in the DOCA-salt model of hypertension in rats.
Peptides.
30(12):2309-15
[DOI] 10.1016/j.peptides.2009.09.005.
[PMID] 19747516.
2009
Ace2 Activation Exerts Antithrombotic Activity
.
40
2009
Angiotensin Type 2 Receptor Improves Cardiac Function and Attenuates Left Ventricular Remodeling Following Myocardial Infarction in the Rat
Hypertension.
54:E71-E72
2009
Angiotensin type 2 receptor-mediated apoptosis of human prostate cancer cells.
Molecular cancer therapeutics.
8(12):3255-65
[DOI] 10.1158/1535-7163.MCT-09-0237.
[PMID] 19996275.
2009
Candesartan pretreatment is cerebroprotective in a rat model of endothelin-1-induced middle cerebral artery occlusion.
Experimental physiology.
94(8):937-46
[DOI] 10.1113/expphysiol.2009.047936.
[PMID] 19429641.
2009
Cardiac Ace2 Activation Protects the Heart Against Hypertension-Induced Fibrosis Involving Erk
Hypertension.
54:E111-E112
2009
Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension.
American journal of respiratory and critical care medicine.
179(11):1048-54
[DOI] 10.1164/rccm.200811-1678OC.
[PMID] 19246717.
2009
New Targets in Pulmonary Hypertension-Another Ace Up the Sleeve
American Journal of Respiratory and Critical Care Medicine.
180
2009
Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene transfer.
Hypertension (Dallas, Tex. : 1979).
54(2):365-71
[DOI] 10.1161/HYPERTENSIONAHA.108.125468.
[PMID] 19564552.
2008
Ace2 Activation Attenuates Monocrotatine-Induced Pulmonary Hypertension in Rats
Journal of Hypertension.
26
2008
Ace2 Activation Prevents Monocrotaline-Induced Pulmonary Hypertension
Hypertension.
52
2008
Angiotensin-(1-7) as An Antihypertensive, Antifibrotic Target
Current Hypertension Reports.
10(9):227-232
[DOI] 10.1007/s11906-008-0043-9.
[PMID] 21615360.
2008
Angiotensin-(1-7) as an antihypertensive, antifibrotic target.
Current hypertension reports.
10(3):227-32
[PMID] 18765095.
2008
Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology.
Hypertension (Dallas, Tex. : 1979).
51(3):712-8
[DOI] 10.1161/HYPERTENSIONAHA.107.100693.
[PMID] 18250366.
2008
Macrophage migration inhibitory factor in hypothalamic paraventricular nucleus neurons decreases blood pressure in spontaneously hypertensive rats.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
22(9):3175-85
[DOI] 10.1096/fj.08-108662.
[PMID] 18535252.
2008
Prevention of Monocrotaline-Induced Pulmonary Hypertension By Lenti-Viral Mediated Gene Delivery of Angiotensin-(1-7)
.
103
2008
Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents.
Hypertension (Dallas, Tex. : 1979).
51(5):1312-7
[DOI] 10.1161/HYPERTENSIONAHA.107.108944.
[PMID] 18391097.
2007
ACE2 overexpression inhibits hypoxia-induced collagen production by cardiac fibroblasts.
Clinical science (London, England : 1979).
113(8):357-64
[PMID] 17600530.
2007
Potentiation of the antihypertensive action of losartan by peripheral overexpression of the ANG II type 2 receptor.
American journal of physiology. Heart and circulatory physiology.
292(2):H727-35
[PMID] 17085538.
2007
Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7).
American journal of physiology. Heart and circulatory physiology.
292(2):H736-42
[PMID] 17098828.
2006
ACE2: A novel therapeutic target for cardiovascular diseases.
Progress in biophysics and molecular biology.
91(1-2):163-98
[PMID] 16009403.
2006
Alterations in aortic vascular reactivity to angiotensin 1-7 in 17-beta-estradiol-treated female SD rats.
Regulatory peptides.
133(1-3):62-7
[PMID] 16219374.
2006
Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension.
American journal of physiology. Heart and circulatory physiology.
290(6):H2417-23
[PMID] 16415071.
2006
Effects of central and peripheral injections of apelin on fluid intake and cardiovascular parameters in rats.
Physiology & behavior.
89(2):221-5
[PMID] 16839572.
2005
Angiotensin-converting enzyme 2 as a novel target for gene therapy for hypertension.
Experimental physiology.
90(3):299-305
[PMID] 15640278.
2005
Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats.
Experimental physiology.
90(5):783-90
[PMID] 16049057.
2004
Angiotensin II type 2 receptor gene transfer elicits cardioprotective effects in an angiotensin II infusion rat model of hypertension.
Physiological genomics.
19(3):255-61
[PMID] 15383639.
2004
Cloning and characterization of a secreted form of angiotensin-converting enzyme 2.
Regulatory peptides.
122(2):61-7
[PMID] 15380922.
2004
Decrease in hypothalamic gamma adducin in rat models of hypertension.
Hypertension (Dallas, Tex. : 1979).
43(2):324-8
[PMID] 14732736.
2004
Elevated blood pressure in normotensive rats produced by ‘knockdown’ of the angiotensin type 2 receptor.
Experimental physiology.
89(3):313-22
[PMID] 15123567.
2004
Prevention of cardiac hypertrophy by angiotensin II type-2 receptor gene transfer.
Hypertension (Dallas, Tex. : 1979).
43(6):1233-8
[PMID] 15166182.
2004
Role of angiotensin II and the subfornical organ in the pharmacological actions of ethanol.
Alcohol and alcoholism (Oxford, Oxfordshire).
39(5):410-7
[PMID] 15289207.
2003
Efficient large-scale production and concentration of HIV-1-based lentiviral vectors for use in vivo.
Physiological genomics.
12(3):221-8
[PMID] 12488511.
2003
Endothelial-independent prevention of high blood pressure in L-NAME-treated rats by angiotensin II type I receptor antisense gene therapy.
Experimental physiology.
88(4):467-73
[PMID] 12861333.
2002
Blood pressure-independent attenuation of cardiac hypertrophy by AT(1)R-AS gene therapy.
Hypertension (Dallas, Tex. : 1979).
39(5):969-75
[PMID] 12019278.
2002
Genetic targeting of the renin-angiotensin system for long-term control of hypertension.
Current hypertension reports.
4(1):25-31
[PMID] 11790288.
2002
Hypertension-linked decrease in the expression of brain gamma-adducin.
Circulation research.
91(7):633-9
[PMID] 12364392.
2002
Large-scale production of retroviral vectors for systemic gene delivery.
Methods in enzymology.
346:562-73
[PMID] 11883091.
2001
Gene therapy attenuates the elevated blood pressure and glucose intolerance in an insulin-resistant model of hypertension.
Journal of hypertension.
19(9):1553-8
[PMID] 11564974.
2001
Gene therapy for cardiovascular disorders: is there a future?
Annals of the New York Academy of Sciences.
953:31-42
[PMID] 11795421.
2001
Gene therapy in cardiovascular disease. Current status.
American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.
1(1):55-66
[PMID] 12173315.
2001
Gene therapy to control hypertension: current studies and future perspectives.
The American journal of the medical sciences.
322(1):1-6
[PMID] 11465240.
2001
Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb?
Physiological genomics.
7(2):79-94
[PMID] 11773594.
2001
Perinatal dietary NaCl level: effect on angiotensin-induced thermal and dipsogenic responses in adult rats.
Physiology & behavior.
72(4):621-7
[PMID] 11282148.
2001
Systemic Delivery of aTransgene in Intact Animals by a Retroviral Vector.
Methods in molecular medicine.
51:67-81
[DOI] 10.1385/1-59259-087-X:67.
[PMID] 21331710.
2001
The future of hypertension therapy: sense, antisense, or nonsense?
Hypertension (Dallas, Tex. : 1979).
37(2 Pt 2):357-64
[PMID] 11230300.
2000
Angiotensin I-converting enzyme antisense gene therapy causes permanent antihypertensive effects in the SHR.
Hypertension (Dallas, Tex. : 1979).
35(1 Pt 2):202-8
[PMID] 10642298.
2000
Angiotensin I-converting enzyme antisense prevents altered renal vascular reactivity, but not high blood pressure, in spontaneously hypertensive rats.
Hypertension (Dallas, Tex. : 1979).
35(1 Pt 2):209-13
[PMID] 10642299.
2000
Attenuation of hypertension by systemic delivery of retroviral vector containing type I angiotensin II receptor antisense cDNA.
Methods (San Diego, Calif.).
22(3):211-8
[PMID] 11071816.
2000
Current perspectives on the use of gene therapy for hypertension.
Circulation research.
87(12):1118-22
[PMID] 11110768.
2000
Effects of inhibition of the renin-angiotensin system on the cardiovascular actions of insulin.
Diabetes, obesity & metabolism.
2(1):3-14
[PMID] 11220351.
2000
Gene therapy for hypertension and restenosis.
Journal of the renin-angiotensin-aldosterone system : JRAAS.
1(3):211-6
[PMID] 11881028.
2000
Inability to induce hypertension in normotensive rat expressing AT(1) receptor antisense.
Circulation research.
86(11):1167-72
[PMID] 10850969.
2000
Retrovirally mediated delivery of angiotensin II type 1 receptor antisense in vitro and in vivo.
Methods in enzymology.
314:581-90
[PMID] 10565039.
2000
Targeting of the renin-angiotensin system by antisense gene therapy: a possible strategy for the long-term control of hypertension.
Journal of hypertension.
18(4):353-62
[PMID] 10779083.
2000
The effect of nitroglycerin on the gravid uterus in sheep and rabbits.
Anesthesia and analgesia.
90(2):337-43
[PMID] 10648318.
1999
Angiotensin II type 1 receptor antisense gene therapy prevents altered renal vascular calcium homeostasis in hypertension.
Hypertension (Dallas, Tex. : 1979).
33(1 Pt 2):360-5
[PMID] 9931130.
1999
Body fluid distribution in rats with cold-induced hypertension.
Physiology & behavior.
65(4-5):879-84
[PMID] 10073495.
1999
Increased tail artery vascular responsiveness to angiotensin II in cold-treated rats.
Canadian journal of physiology and pharmacology.
77(12):974-9
[PMID] 10606444.
1999
Is antisense gene therapy a step in the right direction in the control of hypertension?
The American journal of physiology.
277(2):H423-32
[DOI] 10.1152/ajpheart.1999.277.2.H423.
[PMID] 10444465.
1999
Permanent cardiovascular protection from hypertension by the AT(1) receptor antisense gene therapy in hypertensive rat offspring.
Circulation research.
85(10):e44-50
[PMID] 10559146.
1999
Reversal of hypertension by angiotensin II type 1 receptor antisense gene therapy in the adult SHR.
The American journal of physiology.
277(3):H1260-4
[DOI] 10.1152/ajpheart.1999.277.3.H1260.
[PMID] 10484448.
1999
Sustained inhibition of angiotensin I-converting enzyme (ACE) expression and long-term antihypertensive action by virally mediated delivery of ACE antisense cDNA.
Circulation research.
85(7):614-22
[PMID] 10506486.
1999
The potential use of gene therapy in the control of hypertension.
Drugs of today (Barcelona, Spain : 1998).
35(12):925-30
[PMID] 12973419.
1998
Gravitational biology opportunities planned for the International Space Station.
Journal of gravitational physiology : a journal of the International Society for Gravitational Physiology.
5(1):P189-92
[PMID] 11542348.
1998
Pharmacokinetics and metabolism of [14C]dichloroacetate in male Sprague-Dawley rats. Identification of glycine conjugates, including hippurate, as urinary metabolites of dichloroacetate.
Drug metabolism and disposition: the biological fate of chemicals.
26(11):1134-43
[PMID] 9806957.
1998
Positive effects of acarbose in the diabetic rat are not altered by feeding schedule.
Physiology & behavior.
63(5):867-74
[PMID] 9618010.
1998
Prevention of renovascular and cardiac pathophysiological changes in hypertension by angiotensin II type 1 receptor antisense gene therapy.
Proceedings of the National Academy of Sciences of the United States of America.
95(5):2664-9
[PMID] 9482944.
1997
Effects of chronic treatment with angiotensin II on thermoregulation in rats.
Annals of the New York Academy of Sciences.
813:211-5
[PMID] 9100886.
1997
Losartan versus gene therapy: chronic control of high blood pressure in spontaneously hypertensive rats.
Hypertension (Dallas, Tex. : 1979).
30(3 Pt 1):363-70
[PMID] 9314418.
1996
AT1 receptor density changes during development of hypertension in hyperinsulinemic rats.
Clinical and experimental hypertension (New York, N.Y. : 1993).
18(6):793-810
[PMID] 8842564.
1996
Changes in angiotensin AT1 receptor density during hypertension in fructose-fed rats.
Advances in experimental medicine and biology.
396:49-58
[PMID] 8726685.
1996
Chronic control of high blood pressure in the spontaneously hypertensive rat by delivery of angiotensin type 1 receptor antisense.
Proceedings of the National Academy of Sciences of the United States of America.
93(18):9960-5
[PMID] 8790439.
1996
Effect of acute and chronic losartan treatment on glucose tolerance and insulin sensitivity in fructose-fed rats.
American journal of hypertension.
9(7):662-8
[PMID] 8806978.
1996
Effect of restraint on drug-induced changes in skin and core temperature in biotelemetered rats.
Pharmacology, biochemistry, and behavior.
55(2):219-25
[PMID] 8951958.
1996
Fructose feeding in rats is not associated with sodium retention.
American journal of hypertension.
9(10 Pt 1):1018-23
[PMID] 8896655.
1996
Vascular reactivity to phenylephrine and angiotensin II in hypertensive rats associated with insulin resistance.
Clinical and experimental hypertension (New York, N.Y. : 1993).
18(2):227-42
[PMID] 8869002.
1995
A prodrug approach to increasing the oral potency of a phenolic drug. Part 2. Pharmacodynamics and preliminary bioavailability of an orally administered O-(imidomethyl) derivative of 17 beta-estradiol.
Journal of pharmaceutical sciences.
84(2):174-8
[PMID] 7738796.
1995
Chronic Losartan treatment blocks isoproterenol-induced dipsogenesis.
Physiology & behavior.
58(2):283-6
[PMID] 7568431.
1995
Effects of streptozotocin-induced diabetes and insulin treatment on blood pressure in the male rat.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.).
208(3):300-6
[PMID] 7878070.
1995
The impact of polyamine analogues on the blood pressure of normotensive and hypertensive rats.
Clinical and experimental hypertension (New York, N.Y. : 1993).
17(8):1197-217
[PMID] 8563697.
1994
Effect of chronic losartan potassium treatment on fructose-induced hypertension.
Life sciences.
55(7):PL139-44
[PMID] 8041226.
1993
Effect of insulin on the altered thyroid function and adrenergic responsiveness in the diabetic rat.
Canadian journal of physiology and pharmacology.
71(8):568-75
[PMID] 8306194.
1993
Effects of insulin and acarbose alone and in combination in the female streptozotocin-induced diabetic rat.
Journal of pharmaceutical sciences.
82(12):1209-13
[PMID] 8308697.
1992
Erectile and copulatory dysfunction in chronically diabetic BB/WOR rats.
The American journal of physiology.
263(1 Pt 1):E151-7
[PMID] 1636693.
1992
Role of the adrenal gland in the thermal response to morphine withdrawal in rats.
Canadian journal of physiology and pharmacology.
70(8):1090-5
[PMID] 1473040.
1991
Beneficial effects of dietary acarbose in the streptozotocin-induced diabetic rat.
Metabolism: clinical and experimental.
40(12):1275-82
[PMID] 1961120.
1991
Reduction in aortic smooth muscle beta-adrenergic responsiveness results in enhanced norepinephrine responsiveness in the Dahl salt-sensitive rat.
Clinical and experimental hypertension. Part A, Theory and practice.
13(1):117-32
[PMID] 1850672.
1990
Effects of peripheral administration of naloxone on beta-adrenergic mediated responses.
Pharmacology.
41(3):167-76
[PMID] 2277811.
1990
Glucose modulation of skin temperature responses during morphine withdrawal in the rat.
Psychopharmacology.
102(2):213-20
[PMID] 2274603.
1990
Mechanisms mediating the thermal response to morphine withdrawal in rats.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.).
193(2):129-35
[PMID] 1967837.
1990
The effect of cellular glucoprivation on skin temperature regulation in the rat.
Life sciences.
47(2):107-15
[PMID] 2388522.
1989
Effects of acute central LH-RH administration of the skin temperature response in morphine dependent rats.
Brain research.
494(1):85-94
[PMID] 2670064.
1988
Changes in vascular vasopressin receptors and responsiveness in DOCA/NaCl-treated rats.
Clinical and experimental hypertension. Part A, Theory and practice.
10(4):629-47
[PMID] 2968870.
1988
Dietary potassium, blood pressure and peripheral adrenergic responsiveness in the deoxycorticosterone acetate-salt rat.
Clinical and experimental hypertension. Part A, Theory and practice.
10(3):447-66
[PMID] 3359660.
1988
Thyroxine, renal beta-adrenergic receptors, and dipsogenesis in food-deprived rats.
The American journal of physiology.
254(1 Pt 2):R33-9
[PMID] 2827530.
1987
Alpha-adrenergic mediation of the tail skin temperature response to naloxone in morphine-dependent rats.
Brain research.
426(1):55-61
[PMID] 2825916.
1987
Altered tail-skin temperature responsiveness in streptozotocin-induced diabetic rats.
Life sciences.
41(12):1529-37
[PMID] 3041146.
1987
Beta-adrenergic responsiveness and cardiac autonomic receptors after implantation of the MtTW15 pituitary adenoma in the rat.
Biochemical pharmacology.
36(8):1297-302
[PMID] 3036164.
1987
Effect of chronic estrogen on the skin temperature response to naloxone in morphine-dependent rats.
Canadian journal of physiology and pharmacology.
65(4):563-7
[PMID] 3607603.
1987
Effects of central application of naloxone on the skin temperature response in morphine-dependent rats.
Brain research bulletin.
19(1):81-5
[PMID] 3651842.
1987
Role of hypothermia in the pentobarbital-induced blockade of luteinizing hormone secretion in female rats.
Neuroendocrinology.
46(3):217-21
[PMID] 3658110.
1986
Alterations in vascular alpha and beta adrenergic responsiveness in the Dahl rat: a preliminary report.
Research communications in chemical pathology and pharmacology.
51(1):3-10
[PMID] 3006194.
1986
Differential effects of phentolamine on the responsiveness of aortic and femoral smooth muscle from normotensive and DOCA/NaCl hypertensive rats.
Artery.
13(6):325-39
[PMID] 3778217.
1986
Effects of opioid antagonists and their quaternary analogs on temperature changes in morphine-dependent rats.
Life sciences.
39(20):1845-54
[PMID] 3773644.
1986
Effects of thyroid hormone replacement on beta-adrenergic responsiveness of food-deprived rats.
The American journal of physiology.
250(5 Pt 2):R861-7
[PMID] 3010747.
1986
Possible mechanism for increased beta-adrenergic dipsogenic response in food-deprived rats.
The American journal of physiology.
251(6 Pt 2):R1170-6
[PMID] 3024511.
1986
Regional skin temperature changes in a rat model for the menopausal hot flush.
Maturitas.
8(1):67-76
[PMID] 3702763.
1985
Alterations of testicular function induced by hyperprolactinemia in the rat.
Journal of andrology.
6(3):179-89
[PMID] 4039718.
1985
Effect of beta-adrenergic antagonists on experimentally induced drinking in female rats.
Pharmacology, biochemistry, and behavior.
22(4):553-8
[PMID] 2859613.
1985
Gonadal dysfunction in the spontaneously diabetic BB rat: alterations of testes morphology, serum testosterone and LH.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
17(10):495-501
[PMID] 4065811.
1985
Phentolamine and rat aortic smooth muscle responsiveness to potassium chloride, isoproterenol and norepinephrine.
Pharmacology.
31(2):67-71
[PMID] 4023046.
1985
Role of Peripheral Adrenergic Responsiveness in the Development of DOCA/NaCl Hypertension in Rats.
Pharmaceutical research.
2(6):298-301
[DOI] 10.1023/A:1016345702181.
[PMID] 24271127.
1984
A rapid, quantitative in vivo assay for narcotic antagonists.
Substance and alcohol actions/misuse.
5(2):87-95
[PMID] 6540897.
1984
Effects of elevated prolactin and its normalization on thyroid hormone, cardiac beta-adrenoreceptor number and beta-adrenergic responsiveness.
Life sciences.
34(9):889-98
[PMID] 6321874.
1984
Effects of NaCl on vascular responsiveness in male rats.
Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology.
78(2):369-72
[PMID] 6149082.
1984
Evidence that chronic hyperprolactinemia effects skin temperature regulation through an opioid mechanism.
Neuroendocrinology.
39(4):321-9
[PMID] 6092986.
1984
Soft Drugs VI. The Application of the Inactive Metabolite Approach for Design of Soft β-Blockers1?2.
Pharmaceutical research.
1(3):120-5
[DOI] 10.1023/A:1016376003515.
[PMID] 24277248.
1984
Time course alterations in vascular adrenergic responsiveness in the DOCA/NaCl-treated rat.
Pharmacology.
29(3):173-80
[PMID] 6091157.
1983
Alteration of peripheral beta-adrenergic responsiveness in fasted rats.
Life sciences.
33(14):1385-93
[PMID] 6312234.
1983
Altered peripheral responsiveness to beta-adrenergic stimulation in experimental renal hypertension.
Clinical and experimental hypertension. Part A, Theory and practice.
5(3):367-82
[PMID] 6340860.
1983
Chronic hyperprolactinemia reduces peripheral beta-adrenergic responsiveness in male rats.
Life sciences.
32(11):1213-21
[PMID] 6834986.
1983
Effect of acute administration of isoproterenol and angiotensin II, separately and in combination, on water intake and blood pressure of rats.
Brain research bulletin.
10(3):327-32
[PMID] 6850360.
1983
Effects of chronic hyperprolactinaemia on experimentally induced thirsts in male rats.
The Journal of physiology.
341:75-83
[PMID] 6620192.
1983
Similarities between morphine withdrawal in the rat and the menopausal hot flush.
Life sciences.
32(17):1957-66
[PMID] 6835016.
1983
The effects of food deprivation on beta-adrenergic responsiveness in male rats.
Canadian journal of physiology and pharmacology.
61(10):1101-8
[PMID] 6315202.
1982
Chronic propranolol treatment decreases cardiac beta-adrenoceptors in spontaneously hypertensive rats.
European journal of pharmacology.
78(4):479-82
[PMID] 6281038.
1981
Metabolic responsiveness of spontaneously hypertensive rat to isoproterenol.
The American journal of physiology.
241(4):H497-504
[PMID] 7315974.
1980
beta-adrenergic responsiveness of rats treated chronically with isoproterenol.
Canadian journal of physiology and pharmacology.
58(10):1170-3
[PMID] 6258764.
1980
Changes in beta-adrenergic responsiveness of rats during chronic cold exposure.
Journal of applied physiology: respiratory, environmental and exercise physiology.
49(6):923-9
[PMID] 6254937.
1980
The effect of acute administration of an angiotensin converting enzyme inhibitor, captopril (SQ 14,225), on experimentally induced thirsts in rats.
The Journal of pharmacology and experimental therapeutics.
212(1):53-7
[PMID] 6243360.
1979
Catecholamine-thyroid hormone interaction in cold-acclimated rats.
Federation proceedings.
38(8):2162-9
[PMID] 446768.
1979
Effect of an angiotensin converting enzyme inhibitor (SQ 14,225) on beta-adrenergic and angiotensin-induced thirsts.
European journal of pharmacology.
56(1-2):123-30
[PMID] 223856.
1979
Effect of chronic treatment with desoxycorticosterone on the dipsogenic response of rats to isoproterenol and angiotensin.
Pharmacology.
19(4):165-72
[PMID] 523507.
1979
Effect of cycloheximide on temperature regulation in rats.
Brain research bulletin.
4(3):355-8
[PMID] 487191.
1979
Effect of water temperature on isoproterenol-induced water intake.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.).
160(3):359-62
[PMID] 432244.
1979
Relationship between thermogenic drinking and plasma renin activity in the rat.
Aviation, space, and environmental medicine.
50(7):721-4
[PMID] 384990.
1979
The effect of ambient temperature on beta-adrenergic responsiveness in rats.
Canadian journal of physiology and pharmacology.
57(7):751-5
[PMID] 226256.
1979
Time for loss of increased cardiac responsiveness to isoproterenol in cold-acclimated rats after removal from cold.
Aviation, space, and environmental medicine.
50(2):159-62
[PMID] 444175.
1978
Body mass, composition, and food intake in rabbits during altered acceleration fields.
Journal of applied physiology: respiratory, environmental and exercise physiology.
45(1):51-5
[PMID] 670031.
1978
Inhibition of thermogenic drinking by beta-adrenergic antagonists.
Aviation, space, and environmental medicine.
49(7):861-7
[PMID] 27164.
1978
Mediation of isoproterenol-induced thirst in rats by beta2-adrenergic receptors.
Canadian journal of physiology and pharmacology.
56(3):465-70
[PMID] 208741.
1978
Reduced responsiveness to beta-adrenergic stimulation in renal hypertensive rats.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.).
158(3):363-9
[PMID] 210464.
1977
Gravitational influences upon the maintenance requirements of rabbits.
Life sciences and space research.
15:257-61
[PMID] 11962498.
1974
Effects of season, pregnancy and lactation on thyroxine turnover in the mare.
Journal of animal science.
38(4):811-8
[PMID] 4856698.
Grants
Jan 2014
– Dec 2015
Modulation of the Renin-Angiotensin System for restoration of endothelial progenitor cell function during heart failure
Role: Principal Investigator
Funding: AMER HEART ASSOCIATION
Mar 2011
– Feb 2017
CVD Protection Mechanism involving ACE2/ANG-(1-7) Axis
Role: Project Manager
Funding: NATL INST OF HLTH
May 2010
– Apr 2016
Angiotensin-Converting Enzyme2 in Vascular Endothelial Function
Role: Principal Investigator
Funding: NATL INST OF HLTH NHLBI
Nov 2003
– Nov 2018
Health AFF Katovich Pharmacodynamics Lab
Role: Principal Investigator
Funding: UF FOUNDATION
Contact Details
Phones:
- Business:
- (352) 273-9537
Emails:
- Business:
- katovich@cop.ufl.edu
Addresses:
- Business Mailing:
-
PO Box 115500
GAINESVILLE FL 32611 - Business Street:
-
1600 SW ARCHER RD
P1-33 JHMHC
GAINESVILLE FL 32611